Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | 2 | 3 | 5 | — | — | 8 |
Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | 2 | 3 | 4 | — | — | 7 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 2 | 4 | — | — | 6 |
Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | — | 1 |
Parathyroid neoplasms | D010282 | — | — | — | — | 1 | — | — | 1 |
Primary hyperparathyroidism | D049950 | EFO_0008519 | E21.0 | — | — | 1 | — | — | 1 |
Hypercalcemia | D006934 | HP_0003072 | E83.52 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Evocalcet |
INN | evocalcet |
Description | Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism. It acts as a calcium-sensing receptor agonist.
|
Classification | Small molecule |
Drug class | calcium-sensing receptor (CaSR) agonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C[C@@H](N[C@H]1CCN(c2ccc(CC(=O)O)cc2)C1)c1cccc2ccccc12 |
PDB | — |
CAS-ID | 870964-67-3 |
RxCUI | — |
ChEMBL ID | CHEMBL4297621 |
ChEBI ID | — |
PubChem CID | 71242808 |
DrugBank | DB12388 |
UNII ID | E58MLH082P (ChemIDplus, GSRS) |